Digest Network Come funziona
Network
/
Società
AI
Non verificato

AIM ImmunoTech Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniOncologiaSalute

14 comunicati stampa

Guarda tutti i comunicati
03/11/2025
Biotecnologia
Legge/Diritto/Fisco
Medicina Salute Benessere
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
Fonte
AIM ImmunoTech Inc.
Emittente
GLOBENEWSWIRE
1.00
0
04/09/2025
Biotecnologia
Medicina Salute Benessere
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
Fonte
AIM ImmunoTech Inc.
Emittente
GLOBENEWSWIRE
1.00
0
28/02/2025
Biotecnologia
Annunci Economici
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Fonte
AIM ImmunoTech Inc.
Emittente
GLOBENEWSWIRE
1.00
0
17/12/2024
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Farmaceutica
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
Fonte
AIM ImmunoTech Inc.
Emittente
Business Wire
1.00
0
16/12/2024
Scienza
Finanza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Salute
Farmaceutica
Oncologia
AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card
Fonte
AIM ImmunoTech Inc.
Emittente
Business Wire
1.00
0
12/12/2024
Scienza
Finanza
Biotecnologia
Medicina - Varie
Associazioni/Professionisti
Farmaceutica
Salute
Oncologia
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members
Fonte
AIM ImmunoTech Inc.
Emittente
Business Wire
1.00
0
12/12/2024
Biotecnologia
Annunci Economici
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
Fonte
AIM ImmunoTech Inc.
Emittente
GLOBENEWSWIRE
1.00
0
10/12/2024
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell
Fonte
AIM ImmunoTech Inc.
Emittente
Business Wire
1.00
0
05/12/2024
Scienza
Finanza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Farmaceutica
Salute
Oncologia
ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M. Mitchell
Fonte
AIM ImmunoTech Inc.
Emittente
Business Wire
1.00
0
02/12/2024
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group’s Nominees to the Board
Fonte
AIM ImmunoTech Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0